| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Male | 51 | 2023 | 52 | 12.760 |
Why?
|
| Male | 123 | 2024 | 3337 | 4.950 |
Why?
|
| Testis | 16 | 2022 | 26 | 3.940 |
Why?
|
| Spermatozoa | 17 | 2023 | 22 | 3.880 |
Why?
|
| Humans | 119 | 2024 | 6896 | 3.380 |
Why?
|
| Testosterone | 20 | 2022 | 30 | 3.250 |
Why?
|
| Animals | 50 | 2024 | 729 | 3.240 |
Why?
|
| Azoospermia | 11 | 2019 | 11 | 3.050 |
Why?
|
| Prostatic Neoplasms | 15 | 2015 | 34 | 3.000 |
Why?
|
| Urogenital Abnormalities | 6 | 2022 | 12 | 2.750 |
Why?
|
| Semen Analysis | 13 | 2023 | 13 | 2.590 |
Why?
|
| Fertility | 10 | 2022 | 18 | 2.550 |
Why?
|
| Hypogonadism | 10 | 2019 | 10 | 2.510 |
Why?
|
| Mice | 35 | 2024 | 348 | 2.490 |
Why?
|
| Spermatogenesis | 13 | 2022 | 13 | 2.300 |
Why?
|
| Chromosomes, Human, Y | 8 | 2019 | 9 | 1.840 |
Why?
|
| Reproductive Medicine | 6 | 2020 | 7 | 1.660 |
Why?
|
| Reproductive Techniques, Assisted | 5 | 2018 | 5 | 1.540 |
Why?
|
| Sperm Count | 10 | 2023 | 10 | 1.540 |
Why?
|
| Aging | 6 | 2023 | 39 | 1.420 |
Why?
|
| Genomics | 4 | 2022 | 101 | 1.400 |
Why?
|
| Mutation | 9 | 2020 | 212 | 1.400 |
Why?
|
| Semen | 4 | 2023 | 4 | 1.390 |
Why?
|
| Varicocele | 6 | 2020 | 6 | 1.370 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 231 | 1.360 |
Why?
|
| Oligospermia | 8 | 2016 | 8 | 1.320 |
Why?
|
| Gene Dosage | 5 | 2022 | 13 | 1.280 |
Why?
|
| Ghrelin | 4 | 2016 | 6 | 1.280 |
Why?
|
| E2F1 Transcription Factor | 2 | 2021 | 2 | 1.250 |
Why?
|
| Nuclear Proteins | 5 | 2022 | 52 | 1.160 |
Why?
|
| Female | 27 | 2024 | 3525 | 1.160 |
Why?
|
| Receptors, Androgen | 9 | 2022 | 9 | 1.140 |
Why?
|
| Androgens | 6 | 2022 | 8 | 1.120 |
Why?
|
| Cryptorchidism | 4 | 2022 | 16 | 1.100 |
Why?
|
| Congenital Abnormalities | 4 | 2019 | 17 | 1.060 |
Why?
|
| Chromosome Aberrations | 6 | 2017 | 12 | 1.010 |
Why?
|
| Cisplatin | 2 | 2015 | 10 | 1.010 |
Why?
|
| Adult | 28 | 2020 | 1181 | 1.010 |
Why?
|
| Urology | 6 | 2021 | 7 | 1.000 |
Why?
|
| Genetic Testing | 7 | 2022 | 87 | 1.000 |
Why?
|
| DNA Copy Number Variations | 5 | 2020 | 37 | 0.990 |
Why?
|
| Stem Cell Transplantation | 4 | 2005 | 15 | 0.960 |
Why?
|
| Stem Cells | 5 | 2018 | 29 | 0.960 |
Why?
|
| Chromosome Deletion | 6 | 2024 | 20 | 0.940 |
Why?
|
| Sertoli Cells | 3 | 2022 | 3 | 0.940 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2015 | 12 | 0.940 |
Why?
|
| Risk Factors | 10 | 2020 | 487 | 0.930 |
Why?
|
| Infertility | 3 | 2011 | 5 | 0.930 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 3 | 2019 | 4 | 0.900 |
Why?
|
| Proteomics | 2 | 2014 | 24 | 0.900 |
Why?
|
| Metabolomics | 2 | 2014 | 18 | 0.900 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2022 | 1 | 0.860 |
Why?
|
| Hypospadias | 1 | 2022 | 4 | 0.860 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 39 | 0.850 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2024 | 5 | 0.820 |
Why?
|
| Pregnancy | 12 | 2023 | 216 | 0.820 |
Why?
|
| Paternal Age | 3 | 2017 | 3 | 0.820 |
Why?
|
| Urinary Tract | 3 | 2020 | 10 | 0.810 |
Why?
|
| Transcription Factors | 3 | 2020 | 52 | 0.800 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2020 | 51 | 0.770 |
Why?
|
| Wnt4 Protein | 1 | 2021 | 1 | 0.760 |
Why?
|
| Sequence Deletion | 3 | 2022 | 12 | 0.760 |
Why?
|
| Pregnancy Outcome | 3 | 2023 | 6 | 0.750 |
Why?
|
| Urinary Bladder | 2 | 2018 | 7 | 0.740 |
Why?
|
| Apoptosis | 5 | 2020 | 52 | 0.740 |
Why?
|
| Homozygote | 2 | 2022 | 20 | 0.720 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2020 | 348 | 0.710 |
Why?
|
| Genitalia | 2 | 2017 | 5 | 0.700 |
Why?
|
| Signal Transduction | 6 | 2022 | 132 | 0.700 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 68 | 0.690 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2019 | 4 | 0.690 |
Why?
|
| Spermatogonia | 4 | 2010 | 4 | 0.690 |
Why?
|
| Mice, Inbred C57BL | 9 | 2021 | 92 | 0.680 |
Why?
|
| Protein Array Analysis | 2 | 2019 | 4 | 0.640 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2024 | 41 | 0.640 |
Why?
|
| Penis | 2 | 2017 | 5 | 0.640 |
Why?
|
| Receptors, Ghrelin | 2 | 2015 | 2 | 0.630 |
Why?
|
| Leydig Cells | 4 | 2022 | 4 | 0.630 |
Why?
|
| Aneuploidy | 2 | 2015 | 4 | 0.620 |
Why?
|
| Sperm Injections, Intracytoplasmic | 4 | 2020 | 4 | 0.590 |
Why?
|
| Neoplasms | 3 | 2014 | 128 | 0.580 |
Why?
|
| Testicular Diseases | 2 | 2016 | 2 | 0.570 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 6 | 0.560 |
Why?
|
| Homeodomain Proteins | 2 | 2014 | 20 | 0.560 |
Why?
|
| Phenotype | 7 | 2020 | 257 | 0.550 |
Why?
|
| Exome | 2 | 2019 | 36 | 0.550 |
Why?
|
| Middle Aged | 17 | 2016 | 608 | 0.550 |
Why?
|
| Immunoassay | 1 | 2016 | 10 | 0.540 |
Why?
|
| Andrology | 2 | 2022 | 2 | 0.540 |
Why?
|
| Sperm Motility | 6 | 2023 | 6 | 0.530 |
Why?
|
| Biomarkers, Tumor | 3 | 2014 | 65 | 0.520 |
Why?
|
| Sperm-Ovum Interactions | 2 | 2013 | 2 | 0.520 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2015 | 1 | 0.510 |
Why?
|
| DNA Repair | 1 | 2015 | 3 | 0.510 |
Why?
|
| Haploinsufficiency | 2 | 2019 | 10 | 0.510 |
Why?
|
| Abortion, Spontaneous | 1 | 2015 | 1 | 0.510 |
Why?
|
| Carcinoma | 1 | 2015 | 7 | 0.510 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 14 | 0.500 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 26 | 0.500 |
Why?
|
| Cachexia | 1 | 2015 | 1 | 0.500 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2015 | 1 | 0.500 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 1 | 0.500 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2015 | 6 | 0.500 |
Why?
|
| Otx Transcription Factors | 1 | 2014 | 2 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2014 | 3 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 41 | 0.490 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 3 | 0.480 |
Why?
|
| Urogenital System | 1 | 2014 | 1 | 0.480 |
Why?
|
| R-SNARE Proteins | 1 | 2014 | 1 | 0.480 |
Why?
|
| Estrogens | 1 | 2014 | 3 | 0.480 |
Why?
|
| Developmental Disabilities | 1 | 2014 | 43 | 0.480 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 31 | 0.470 |
Why?
|
| Genome, Human | 1 | 2014 | 86 | 0.470 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 71 | 0.460 |
Why?
|
| Cholecalciferol | 1 | 2013 | 3 | 0.460 |
Why?
|
| Steroid Hydroxylases | 1 | 2013 | 10 | 0.460 |
Why?
|
| Biomedical Research | 3 | 2010 | 27 | 0.460 |
Why?
|
| Sex Chromosome Aberrations | 4 | 2019 | 6 | 0.450 |
Why?
|
| Phosphoproteins | 2 | 2004 | 14 | 0.450 |
Why?
|
| Hormone Replacement Therapy | 4 | 2015 | 5 | 0.450 |
Why?
|
| DNA Methylation | 1 | 2014 | 115 | 0.450 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 126 | 0.440 |
Why?
|
| Risk Assessment | 5 | 2020 | 137 | 0.440 |
Why?
|
| Brain | 2 | 2004 | 80 | 0.430 |
Why?
|
| Pregnancy Rate | 3 | 2018 | 3 | 0.430 |
Why?
|
| Animals, Newborn | 2 | 2021 | 32 | 0.420 |
Why?
|
| Mice, Knockout | 6 | 2020 | 59 | 0.420 |
Why?
|
| Pedigree | 3 | 2017 | 59 | 0.410 |
Why?
|
| Case-Control Studies | 8 | 2017 | 215 | 0.410 |
Why?
|
| Infertility, Female | 2 | 2020 | 4 | 0.400 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 48 | 0.400 |
Why?
|
| Editorial Policies | 1 | 2011 | 1 | 0.390 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 5 | 0.390 |
Why?
|
| Reproductive Health | 3 | 2022 | 12 | 0.390 |
Why?
|
| Fertilization in Vitro | 5 | 2020 | 5 | 0.390 |
Why?
|
| Trinucleotide Repeats | 3 | 2013 | 3 | 0.380 |
Why?
|
| Pseudogenes | 1 | 2011 | 1 | 0.380 |
Why?
|
| Genetic Therapy | 2 | 2008 | 7 | 0.380 |
Why?
|
| Endocrinology | 2 | 2020 | 2 | 0.380 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 101 | 0.380 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2010 | 8 | 0.380 |
Why?
|
| Cryopreservation | 1 | 2010 | 5 | 0.370 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 4 | 0.370 |
Why?
|
| Sexual Development | 1 | 2010 | 3 | 0.370 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 8 | 0.370 |
Why?
|
| Young Adult | 10 | 2020 | 647 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2010 | 11 | 0.370 |
Why?
|
| RNA, Untranslated | 1 | 2010 | 7 | 0.370 |
Why?
|
| Karyotyping | 3 | 2019 | 11 | 0.370 |
Why?
|
| Flow Cytometry | 3 | 2018 | 32 | 0.350 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2016 | 6 | 0.350 |
Why?
|
| Kidney Diseases | 2 | 2020 | 71 | 0.340 |
Why?
|
| Cell Cycle | 2 | 2021 | 18 | 0.320 |
Why?
|
| Reproduction | 3 | 2022 | 7 | 0.310 |
Why?
|
| Adolescent | 8 | 2020 | 2197 | 0.310 |
Why?
|
| Ethics, Research | 2 | 2005 | 3 | 0.310 |
Why?
|
| Global Health | 2 | 2021 | 15 | 0.310 |
Why?
|
| Scientific Misconduct | 1 | 2007 | 1 | 0.310 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 20 | 0.300 |
Why?
|
| Prevalence | 3 | 2015 | 146 | 0.290 |
Why?
|
| World Health Organization | 3 | 2018 | 8 | 0.290 |
Why?
|
| Dietary Supplements | 4 | 2020 | 25 | 0.280 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 49 | 0.270 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 22 | 0.270 |
Why?
|
| Tissue Adhesions | 2 | 2016 | 9 | 0.270 |
Why?
|
| Genetic Engineering | 1 | 2005 | 1 | 0.270 |
Why?
|
| Molecular Biology | 1 | 2005 | 3 | 0.270 |
Why?
|
| Cell Differentiation | 3 | 2019 | 59 | 0.260 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2005 | 1 | 0.260 |
Why?
|
| Texas | 5 | 2019 | 20 | 0.250 |
Why?
|
| Quality of Life | 3 | 2023 | 140 | 0.250 |
Why?
|
| Germ Cells | 1 | 2004 | 5 | 0.250 |
Why?
|
| Cell Cycle Proteins | 3 | 2019 | 18 | 0.250 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 55 | 0.240 |
Why?
|
| Child, Preschool | 4 | 2020 | 1569 | 0.240 |
Why?
|
| Genetic Markers | 2 | 2014 | 22 | 0.240 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 9 | 0.240 |
Why?
|
| Receptors, LH | 1 | 2004 | 1 | 0.240 |
Why?
|
| Meningomyelocele | 1 | 2024 | 1 | 0.240 |
Why?
|
| Age Factors | 4 | 2019 | 210 | 0.240 |
Why?
|
| Base Sequence | 5 | 2015 | 81 | 0.230 |
Why?
|
| Models, Biological | 2 | 2021 | 65 | 0.230 |
Why?
|
| Prostate | 5 | 2014 | 7 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 11 | 0.230 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 99 | 0.220 |
Why?
|
| RNA, Messenger | 3 | 2013 | 115 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 199 | 0.220 |
Why?
|
| Risk | 4 | 2024 | 41 | 0.220 |
Why?
|
| Meiosis | 4 | 2008 | 4 | 0.220 |
Why?
|
| Orchiectomy | 1 | 2003 | 2 | 0.220 |
Why?
|
| Molecular Sequence Data | 6 | 2015 | 71 | 0.220 |
Why?
|
| Proteins | 3 | 2009 | 27 | 0.220 |
Why?
|
| Models, Animal | 2 | 2015 | 10 | 0.220 |
Why?
|
| Glutamine | 1 | 2003 | 2 | 0.220 |
Why?
|
| Child | 6 | 2020 | 3364 | 0.220 |
Why?
|
| Infant | 3 | 2020 | 1446 | 0.220 |
Why?
|
| Ubiquitins | 1 | 2022 | 1 | 0.220 |
Why?
|
| Peptides | 1 | 2003 | 11 | 0.220 |
Why?
|
| Potassium | 1 | 2022 | 9 | 0.210 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2022 | 4 | 0.210 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 23 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 4 | 2014 | 9 | 0.210 |
Why?
|
| Cells, Cultured | 3 | 2018 | 84 | 0.210 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 7 | 0.210 |
Why?
|
| Men's Health | 1 | 2022 | 1 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 55 | 0.200 |
Why?
|
| Rats | 4 | 2016 | 106 | 0.200 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2012 | 9 | 0.200 |
Why?
|
| Blood-Testis Barrier | 1 | 2021 | 1 | 0.190 |
Why?
|
| Research Support as Topic | 1 | 2021 | 6 | 0.190 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 11 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2021 | 5 | 0.190 |
Why?
|
| Body Weight | 3 | 2016 | 52 | 0.190 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 17 | 0.190 |
Why?
|
| Disease Progression | 5 | 2015 | 111 | 0.190 |
Why?
|
| Aged | 8 | 2014 | 378 | 0.180 |
Why?
|
| Eye | 1 | 2020 | 3 | 0.180 |
Why?
|
| Chromosome Duplication | 1 | 2020 | 3 | 0.180 |
Why?
|
| Eye Abnormalities | 1 | 2020 | 6 | 0.180 |
Why?
|
| Societies, Medical | 4 | 2020 | 51 | 0.180 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2018 | 2 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2019 | 289 | 0.180 |
Why?
|
| Sexual Behavior | 2 | 2022 | 38 | 0.180 |
Why?
|
| Prostatic Hyperplasia | 3 | 2004 | 3 | 0.180 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 4 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 7 | 0.170 |
Why?
|
| Retrospective Studies | 8 | 2019 | 1296 | 0.170 |
Why?
|
| Transcription, Genetic | 2 | 2018 | 44 | 0.170 |
Why?
|
| Intellectual Disability | 1 | 2019 | 35 | 0.170 |
Why?
|
| Fertility Preservation | 1 | 2019 | 7 | 0.160 |
Why?
|
| United States | 5 | 2021 | 669 | 0.160 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 4 | 0.160 |
Why?
|
| Erectile Dysfunction | 1 | 2018 | 1 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 14 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2018 | 6 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2020 | 58 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 21 | 0.160 |
Why?
|
| Iron | 1 | 2018 | 14 | 0.160 |
Why?
|
| Prostatectomy | 3 | 2009 | 4 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2018 | 2 | 0.160 |
Why?
|
| Cell Adhesion | 1 | 2018 | 9 | 0.150 |
Why?
|
| Gene Deletion | 1 | 2018 | 13 | 0.150 |
Why?
|
| HEK293 Cells | 1 | 2018 | 32 | 0.150 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 13 | 0.150 |
Why?
|
| RNA Interference | 1 | 2018 | 16 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 41 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 1 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 117 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 3 | 2018 | 84 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 3 | 0.140 |
Why?
|
| DNA Damage | 1 | 2017 | 9 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 2016 | 1 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 115 | 0.140 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 2 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 5 | 0.140 |
Why?
|
| Species Specificity | 2 | 2014 | 10 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2016 | 12 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 6 | 0.140 |
Why?
|
| Sleep | 1 | 2016 | 37 | 0.140 |
Why?
|
| Klinefelter Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
|
| Vas Deferens | 1 | 2016 | 1 | 0.140 |
Why?
|
| Kallmann Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
|
| Male Urogenital Diseases | 1 | 2016 | 1 | 0.140 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hypopituitarism | 1 | 2016 | 2 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2009 | 8 | 0.140 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 18 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 13 | 0.140 |
Why?
|
| Family Planning Services | 1 | 2016 | 2 | 0.130 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2006 | 6 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 15 | 0.130 |
Why?
|
| Life Style | 3 | 2023 | 24 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 35 | 0.130 |
Why?
|
| Time Factors | 3 | 2011 | 250 | 0.130 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 99 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 71 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2006 | 42 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 3 | 0.130 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 4 | 0.130 |
Why?
|
| Chorionic Gonadotropin | 1 | 2015 | 1 | 0.130 |
Why?
|
| Biological Clocks | 1 | 2015 | 1 | 0.130 |
Why?
|
| Histones | 1 | 2015 | 16 | 0.130 |
Why?
|
| Age Distribution | 1 | 2015 | 31 | 0.130 |
Why?
|
| Abortion, Habitual | 1 | 2015 | 1 | 0.130 |
Why?
|
| Organ Size | 1 | 2015 | 14 | 0.130 |
Why?
|
| Homeostasis | 1 | 2015 | 8 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2015 | 4 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2014 | 3 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2014 | 3 | 0.120 |
Why?
|
| Chromosomes, Human, X | 1 | 2014 | 6 | 0.120 |
Why?
|
| Genetic Counseling | 1 | 2014 | 9 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 45 | 0.120 |
Why?
|
| Scrotum | 3 | 2020 | 3 | 0.120 |
Why?
|
| Cell Separation | 2 | 2004 | 7 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 8 | 0.120 |
Why?
|
| CpG Islands | 1 | 2014 | 53 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2020 | 622 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2014 | 17 | 0.120 |
Why?
|
| Smoking | 1 | 2014 | 22 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2014 | 7 | 0.120 |
Why?
|
| Luteinizing Hormone | 3 | 2018 | 5 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2013 | 525 | 0.120 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2013 | 3 | 0.110 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 2 | 2004 | 3 | 0.110 |
Why?
|
| Mice, SCID | 1 | 2013 | 13 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 15 | 0.110 |
Why?
|
| Vasectomy | 1 | 2013 | 1 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 38 | 0.110 |
Why?
|
| Forecasting | 2 | 2022 | 22 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2014 | 174 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 2 | 0.110 |
Why?
|
| RNA Editing | 1 | 2013 | 2 | 0.110 |
Why?
|
| Environmental Pollution | 1 | 2013 | 1 | 0.110 |
Why?
|
| Genitalia, Male | 1 | 2013 | 1 | 0.110 |
Why?
|
| Mass Media | 1 | 2013 | 2 | 0.110 |
Why?
|
| Cricetinae | 1 | 2013 | 4 | 0.110 |
Why?
|
| Follicle Stimulating Hormone | 3 | 2018 | 3 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2013 | 18 | 0.110 |
Why?
|
| Anal Canal | 1 | 2013 | 25 | 0.110 |
Why?
|
| Biopsy | 2 | 2010 | 60 | 0.110 |
Why?
|
| Paternity | 1 | 2012 | 1 | 0.110 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2012 | 9 | 0.110 |
Why?
|
| Sex Ratio | 1 | 2012 | 1 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 122 | 0.110 |
Why?
|
| Steroids | 2 | 2002 | 16 | 0.100 |
Why?
|
| Biomarkers | 1 | 2013 | 136 | 0.100 |
Why?
|
| Publishing | 2 | 2022 | 8 | 0.100 |
Why?
|
| Sperm Head | 1 | 2011 | 1 | 0.100 |
Why?
|
| Egg Proteins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Retirement | 1 | 2011 | 2 | 0.100 |
Why?
|
| Incidence | 3 | 2019 | 133 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2020 | 46 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2011 | 54 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2010 | 5 | 0.090 |
Why?
|
| Body Height | 1 | 2011 | 34 | 0.090 |
Why?
|
| Stem Cell Research | 1 | 2010 | 1 | 0.090 |
Why?
|
| DNA Replication | 1 | 2010 | 3 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2010 | 26 | 0.090 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2010 | 1 | 0.090 |
Why?
|
| Counseling | 2 | 2020 | 28 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 48 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 47 | 0.090 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 35 | 0.090 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 19 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 108 | 0.090 |
Why?
|
| Urologic Diseases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Sperm Capacitation | 1 | 2010 | 1 | 0.090 |
Why?
|
| Manuals as Topic | 1 | 2010 | 2 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 19 | 0.090 |
Why?
|
| Gene Expression | 5 | 2013 | 67 | 0.090 |
Why?
|
| Kidney | 2 | 2020 | 94 | 0.080 |
Why?
|
| Biology | 1 | 2008 | 1 | 0.080 |
Why?
|
| Sex Determination Processes | 1 | 2008 | 1 | 0.080 |
Why?
|
| Insulin | 1 | 2009 | 50 | 0.080 |
Why?
|
| Cell Communication | 1 | 2008 | 12 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2008 | 9 | 0.080 |
Why?
|
| Disorders of Sex Development | 1 | 2008 | 10 | 0.080 |
Why?
|
| Obesity | 2 | 2023 | 125 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 32 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 25 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 1 | 2006 | 26 | 0.070 |
Why?
|
| COS Cells | 2 | 2003 | 19 | 0.070 |
Why?
|
| Transfection | 2 | 2003 | 22 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2017 | 2 | 0.070 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2005 | 1 | 0.070 |
Why?
|
| Dogs | 1 | 2005 | 17 | 0.070 |
Why?
|
| Research | 1 | 2005 | 13 | 0.070 |
Why?
|
| Diet | 1 | 2005 | 52 | 0.060 |
Why?
|
| Transcription Factor TFIID | 1 | 2005 | 1 | 0.060 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2005 | 1 | 0.060 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2005 | 13 | 0.060 |
Why?
|
| Tissue Engineering | 1 | 2005 | 1 | 0.060 |
Why?
|
| Embryo Research | 1 | 2005 | 1 | 0.060 |
Why?
|
| Rhodamine 123 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 59 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 14 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 336 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2004 | 11 | 0.060 |
Why?
|
| Seminiferous Tubules | 1 | 2004 | 1 | 0.060 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Folic Acid Deficiency | 1 | 2024 | 3 | 0.060 |
Why?
|
| Penetrance | 1 | 2024 | 8 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 8 | 0.060 |
Why?
|
| Folic Acid | 1 | 2024 | 17 | 0.060 |
Why?
|
| DiGeorge Syndrome | 1 | 2024 | 8 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 7 | 0.060 |
Why?
|
| Spinal Dysraphism | 1 | 2024 | 9 | 0.060 |
Why?
|
| Synaptonemal Complex | 1 | 2003 | 1 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2003 | 5 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 5 | 0.060 |
Why?
|
| Heterozygote | 1 | 2003 | 26 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 149 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 4 | 0.060 |
Why?
|
| Point Mutation | 1 | 2003 | 7 | 0.060 |
Why?
|
| Ejaculation | 1 | 2003 | 1 | 0.050 |
Why?
|
| Sex Chromosome Disorders | 1 | 2003 | 1 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 9 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2003 | 2 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2003 | 2 | 0.050 |
Why?
|
| Neuroglia | 1 | 2002 | 4 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 4 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2002 | 23 | 0.050 |
Why?
|
| Reproductive Techniques | 1 | 2002 | 1 | 0.050 |
Why?
|
| Seminal Plasma Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Peer Review | 1 | 2022 | 2 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 50 | 0.050 |
Why?
|
| Neurons | 1 | 2002 | 19 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2002 | 5 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 7 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2002 | 40 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 77 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2002 | 17 | 0.050 |
Why?
|
| Leptin | 1 | 2022 | 4 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 8 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Ligases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2009 | 151 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 5 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2020 | 1 | 0.050 |
Why?
|
| Sperm Retrieval | 1 | 2020 | 1 | 0.050 |
Why?
|
| Leadership | 1 | 2021 | 12 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 1 | 0.050 |
Why?
|
| Gonadotropins | 1 | 2020 | 5 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2020 | 9 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 6 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2019 | 816 | 0.050 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 2 | 0.040 |
Why?
|
| Xenopus laevis | 1 | 2019 | 1 | 0.040 |
Why?
|
| Nephrons | 1 | 2019 | 2 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 30 | 0.040 |
Why?
|
| Reproductive Health Services | 1 | 2019 | 3 | 0.040 |
Why?
|
| Fathers | 1 | 2019 | 7 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 6 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2011 | 11 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 11 | 0.040 |
Why?
|
| Mothers | 1 | 2019 | 33 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2018 | 1 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2018 | 14 | 0.040 |
Why?
|
| Graft Survival | 1 | 2018 | 31 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 1 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2018 | 47 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 115 | 0.040 |
Why?
|
| Prolactin | 1 | 2017 | 3 | 0.040 |
Why?
|
| Estradiol | 1 | 2017 | 9 | 0.040 |
Why?
|
| Self Report | 1 | 2016 | 42 | 0.030 |
Why?
|
| Smad6 Protein | 1 | 2016 | 1 | 0.030 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2016 | 2 | 0.030 |
Why?
|
| Smad7 Protein | 1 | 2016 | 3 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2016 | 1 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 15 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 10 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2015 | 2 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 11 | 0.030 |
Why?
|
| Peritoneum | 1 | 2015 | 16 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 304 | 0.030 |
Why?
|
| Inflammation | 1 | 2016 | 51 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2008 | 19 | 0.030 |
Why?
|
| Embryo Loss | 1 | 2015 | 1 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 48 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 46 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2006 | 12 | 0.030 |
Why?
|
| Mutation, Missense | 2 | 2006 | 28 | 0.030 |
Why?
|
| Death | 1 | 2014 | 2 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 13 | 0.030 |
Why?
|
| California | 1 | 2014 | 15 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 34 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 28 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 56 | 0.030 |
Why?
|
| Drug Implants | 1 | 2013 | 1 | 0.030 |
Why?
|
| Gels | 1 | 2013 | 1 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2004 | 7 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 24 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 150 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2013 | 7 | 0.030 |
Why?
|
| Registries | 1 | 2013 | 92 | 0.030 |
Why?
|
| Acrosome | 1 | 2011 | 1 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 16 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 35 | 0.020 |
Why?
|
| Prognosis | 1 | 2008 | 211 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 4 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2006 | 8 | 0.020 |
Why?
|
| Israel | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 6 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2006 | 9 | 0.020 |
Why?
|
| DNA Primers | 1 | 2006 | 30 | 0.020 |
Why?
|
| Europe | 1 | 2006 | 37 | 0.020 |
Why?
|
| Retroelements | 1 | 2005 | 1 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2006 | 90 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2005 | 6 | 0.020 |
Why?
|
| Haplotypes | 1 | 2006 | 91 | 0.020 |
Why?
|
| Spermatids | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cell Division | 1 | 2005 | 12 | 0.020 |
Why?
|
| Alleles | 1 | 2006 | 214 | 0.020 |
Why?
|
| Embryo Transfer | 1 | 2004 | 1 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2004 | 1 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 33 | 0.010 |
Why?
|
| ROC Curve | 1 | 2004 | 22 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 56 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 23 | 0.010 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2003 | 2 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 3 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 6 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2003 | 30 | 0.010 |
Why?
|
| Threonine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Metribolone | 1 | 2002 | 1 | 0.010 |
Why?
|
| Dihydrotestosterone | 1 | 2002 | 2 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 7 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2002 | 5 | 0.010 |
Why?
|
| Alanine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Drug Stability | 1 | 2002 | 4 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2002 | 14 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 7 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 7 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 19 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 26 | 0.010 |
Why?
|
| Relaxin | 1 | 2002 | 1 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 8 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 94 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2002 | 3 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2002 | 2 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 7 | 0.010 |
Why?
|
| Growth | 1 | 2002 | 11 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2002 | 5 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 14 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 29 | 0.010 |
Why?
|